COMMERCIAL PLEDGE AGREEMENTCommercial Pledge Agreement • August 12th, 2022 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.
TRIPLE ASTERIKS DENOTE OMISSIONS SUBLICENSE AGREEMENT by and between CASI PHARMACEUTICALS, INC. and BEIJING TIANSHI TONGDA PHARMACEUTICALS TECHNOLOGY CO., LTD entered into as of May 23, 2022Sublicense Agreement • August 12th, 2022 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This SUBLICENSE AGREEMENT (this “Agreement”) is entered into as of May 23, 2022 (the “Effective Date”) by and between BEIJING TIANSHI TONGDA PHARMACEUTICALS TECHNOLOGY CO., LTD, having a place of business at Room 101-31, Floor 1, Building 2, 1# Jiuqiao Road, Beijing Economic and Technological Development Zone (Daxing), Beijing, China (“TIANSHI”), and CASI PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, having its principal place of business at 9620 Medical Center Drive, Suite 300, Rockville, MD 20850 (“CASI”). CASI and TIANSHI are sometimes referred to individually as a “Party” and collectively as the “Parties.”
